Outlook Therapeutics reports FY2026 Q3 results; highlights LYTENAVA FDA approval
Outlook Therapeutics (OTLKW) reports Third Quarter Fiscal Year 2026 financial results and a business update highlighting FDA approval of LYTENAVA™.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.